For example, a small-molecule inhibitor of nuclear PARP-1/2 activity was developed to treat amyotrophic lateral sclerosis (ALS) by reducing the formation of cytoplasmic TDP-43 aggregates in mammalian cells42. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.